Cyclin D1 Polymorphism and Colorectal Cancer Risk
Author Information
Author(s): Schernhammer E S, Tranah G J, Giovannucci E, Chan A T, Ma J, Colditz G A, Hunter D J, Willett W C, Fuchs C S
Primary Institution: Brigham and Women's Hospital and Harvard Medical School
Hypothesis
Does the CCND1 A870G polymorphism influence the risk of colorectal cancer and adenoma?
Conclusion
The CCND1 A870G polymorphism does not show statistically significant associations with the risk of colorectal cancer or adenoma.
Supporting Evidence
- The CCND1 polymorphism did not show statistically significant associations to risk of colorectal cancer or adenoma.
- The A870G genotype may enhance the protective effect of postmenopausal oestrogen use on colorectal neoplasia.
- Among women, the CCND1 A870G polymorphism was associated with a modest, although nonsignificantly elevated risk of colorectal cancer.
Takeaway
This study looked at a gene that might affect the risk of getting colon cancer. They found that having a certain version of this gene didn't really change the chances of getting cancer or polyps.
Methodology
The study analyzed data from three large cohorts, assessing the association between the CCND1 A870G genotype and colorectal cancer and adenoma risk using logistic regression.
Potential Biases
Potential detection bias due to self-reported diagnoses of colorectal cancer and adenoma.
Limitations
The study did not specify whether participants underwent colonoscopy or sigmoidoscopy, which may limit the generalizability of adenoma findings.
Participant Demographics
Participants included women from the Nurses' Health Study and men from the Health Professionals' Follow-Up Study and Physicians' Health Study.
Statistical Information
P-Value
0.06
Confidence Interval
95% CI, 0.82–1.32
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website